Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$43.21 +1.50 (+3.59%)

Closing price 03:59 PM Eastern

Extended Trading

$43.47 +0.26 (+0.61%)

As of 07:13 PM Eastern

Compare

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
1

Hold
14

Buy
3

Based on 18 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 1 has given a sell rating, 14 have given a hold rating, and 3 have given a buy rating for NVO.

Consensus Price Target

$64.94
50.29% Upside

According to the 18 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $64.94. The highest price target for NVO is $175.00, while the lowest price target for NVO is $40.00. The average price target represents a forecasted upside of 50.29% from the current price of $43.21.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Analyst Ratings Over Time

Type	Current Forecast 9/17/25 to 9/17/26	1 Month Ago 8/18/25 to 8/18/26	3 Months Ago 6/19/25 to 6/19/26	1 Year Ago 9/17/24 to 9/17/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)
Hold	14 Hold rating(s)	16 Hold rating(s)	18 Hold rating(s)	9 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$64.94	$64.94	$65.56	$81.00
Forecasted Upside	50.29% Upside	42.06% Upside	51.77% Upside	39.18% Upside
Consensus Rating	Hold	Hold	Hold	Hold

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Healthcare Companies	Broader Market
Consensus Rating Score	2.11	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	55.74% Upside	752.92% Upside	18.17% Upside
News Sentiment Rating	Neutral News See Recent NVO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/10/2026	HSBC 3 of 5 stars		Reiterated Rating	Hold
8/27/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Downgrade	Hold ➝ Sell
8/12/2026	Berenberg Bank 2 of 5 stars	Kerry Holford Not Rated	Set Target		$47.00	-0.46%
8/11/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/6/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform	$47.00	+5.67%
8/5/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Sell (D+) ➝ Hold (C-)
7/20/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral
6/19/2026	Nordea Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
3/26/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Peer Perform
3/18/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+367.93%
My top 3 AI picks for the next decade (Ad) Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. Click here to get all three AI stock names from Alexander Green
3/10/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$42.00	+5.60%
3/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thibault Boutherin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$40.00	+5.99%
3/2/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$63.00 ➝ $41.00	+9.34%
2/24/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
2/24/2026	Kepler Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/12/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Hold
1/9/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$73.50	+28.19%
12/8/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Eade Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
9/16/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
8/22/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/13/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
8/5/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight
4/17/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/3/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$160.00 ➝ $160.00	+49.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:15 PM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 14, 2026. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

Novo Nordisk received approval in China for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 receptor agonist approved in the country for this liver disease, which expands the drug's potential beyond obesity and diabetes into a new therapeutic area in a massive market.
The company is executing a significant share repurchase program of up to DKK 15 billion over a 12-month period starting in February 2026, which signals management's confidence in the company's value and provides direct support to shareholders by reducing the number of outstanding shares.
Novo Nordisk recently rebranded to simply "Novo" and introduced a new cultural framework called "The Novo Way" to increase speed and focus, a strategic move aimed at winning back market share in the competitive obesity drug market against rivals like Eli Lilly.
With a current stock price of $43.47 and a P/E ratio of 10.63, the stock is trading at a significant discount to its 52-week high of $64.16, offering a potentially attractive entry point for investors who believe the recent valuation compression has already priced in substantial execution and competitive risks.
Analysts maintain a consensus price target of $64.94, which represents a substantial upside potential from the current trading levels, suggesting that the market's current pessimism may be excessive given the company's strong margins and free cash flow generation.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Morgan Stanley downgraded the stock to Underweight, citing muted growth expectations, patent risks associated with the semaglutide patent cliff, and rising competitive pressure from Eli Lilly, which has contributed to weak investor sentiment and a significant decline in the stock's value.
The stock has experienced a severe drawdown, falling approximately 12% in 2026 after losing more than half of its value in 2025, marking its worst year since 1984, which indicates deep-seated concerns about the company's ability to sustain its previous growth trajectory.
Short interest in the stock has been rising, with shares shorted increasing to over 31.6 million in the most recent reporting period, suggesting that a significant portion of the market is betting against the company's future performance and potential for further price declines.
Novo Nordisk recently cut its dividend, with the most recent payout representing a yield that has been adjusted downward, which may be a concern for income-focused investors who rely on consistent and growing dividend payments from their pharmaceutical holdings.
The company faces intense competition in the GLP-1 weight-management market, where rivals are aggressively expanding their own product lines, creating a risk that Novo Nordisk may lose market share and pricing power as the competitive landscape becomes more fragmented and price-sensitive.

NVO Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $64.94, with a high forecast of $175.00 and a low forecast of $40.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There is currently 1 sell rating, 14 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 50.29% based on their 12-month stock forecasts.

Over the previous 90 days, Novo Nordisk A/S's stock had 3 upgrades and 3 downgrades by analysts.

Novo Nordisk A/S has been rated by research analysts at Berenberg Bank, BMO Capital Markets, Citigroup, Deutsche Bank Aktiengesellschaft, HSBC, Nordea Equity Research, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Novo Nordisk A/S less than other "healthcare" companies. The consensus rating score for Novo Nordisk A/S is 2.11 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat monitors more than a dozen sources for Novo Nordisk A/S analyst ratings, with the most recent rating issued on 9/10/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case

NVO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S Bull Case

Novo Nordisk A/S Bear Case

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2026?

Should I buy or sell Novo Nordisk A/S stock right now?

Does Novo Nordisk A/S's stock price have much upside?

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Novo Nordisk A/S?

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case